Form 4: Fulgent Genetics COO Sells Shares for Tax Obligations

Fulgent Genetics' President and COO, Jian Xie, sold 1,140 shares of common stock to cover tax liabilities from vested restricted stock units.

Summary

• Jian Xie, President and COO of Fulgent Genetics, Inc. (FLGT), reported a sale of common stock.
• The transaction involved 1,140 shares of common stock.
• The shares were sold on December 2, 2025, at a weighted-average price of $28.3318 per share.
• The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 28, 2022.
• Following the transaction, Mr. Xie directly beneficially owns 336,749 shares and indirectly owns 220,816 shares through The Hsieh Family Dynasty Trust.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: A routine insider transaction for tax purposes, not indicative of management's view on the company's future performance.

Positives

• Vesting of restricted stock units (RSUs) indicates compensation for the executive.

Negatives

• Reduction in direct beneficial ownership by 1,140 shares.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Management Comments

• The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units.

Industry Context

This insider transaction is a routine event related to executive compensation and does not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, pre-scheduled transaction for tax purposes, not signaling a change in company fundamentals or executive confidence.

Key Dates

Recommendation

The filing details a routine insider sale by the President and COO to cover tax obligations from vested restricted stock units, executed under a Rule 10b5-1 plan. This type of transaction is generally not indicative of management's sentiment regarding the company's future prospects and does not provide new information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this event is neutral.

Keywords

Fulgent Genetics, FLGT, insider trading, Form 4, stock sale, restricted stock units, RSU, executive compensation, Jian Xie